Laser capture microdissection

MR Emmert-Buck, RF Bonner, PD Smith, RF Chuaqui… - Science, 1996 - science.org
Laser capture microdissection (LCM) under direct microscopic visualization permits rapid
one-step procurement of selected human cell populations from a section of complex, …

MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road

CJ Caunt, MJ Sale, PD Smith, SJ Cook - Nature Reviews Cancer, 2015 - nature.com
The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …

Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays

…, M Bittner, Y Chen, SB Leighton, T Pohida, PD Smith… - Cancer Research, 1998 - AACR
Several forms of human sarcoma, lymphoma, and leukemia are characterized by somatically
acquired chromosome translocations that result in fusion genes that encode chimeric …

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo …

…, R Jenkins, M Cockerill, S Cartlidge, PD Smith - Molecular cancer …, 2007 - AACR
Constitutive activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated
protein kinase (MAPK) signaling pathway in human cancers is often associated with …

Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer

AN Brooks, E Kilgour, PD Smith - Clinical cancer research, 2012 - AACR
The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling axis plays
an important role in normal organ, vascular, and skeletal development. Deregulation of …

Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer

…, PW Bishop, A White, SE Critchlow, PD Smith… - Clinical Cancer …, 2014 - AACR
Purpose: The monocarboxylate transporter 1 (MCT1) inhibitor, AZD3965, is undergoing phase
I evaluation in the United Kingdom. AZD3965 is proposed, via lactate transport modulation…

Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models

…, ELC O'Brien, CH Barnes, H Brown, PD Smith… - Cancer research, 2015 - AACR
Resistance to targeted EGFR inhibitors is likely to develop in EGFR-mutant lung cancers.
Early identification of innate or acquired resistance mechanisms to these agents is essential to …

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)

…, RS Finn, N Rosen, NK Hayward, T French, PD Smith - Cancer research, 2010 - AACR
Selumetinib (AZD6244, ARRY-142886) is a selective, non–ATP-competitive inhibitor of
mitogen-activated protein/extracellular signal–regulated kinase kinase (MEK)-1/2. The range of …

Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells

…, W Deng, SE Woodman, K Komurov, P Ram, PD Smith… - Cancer research, 2010 - AACR
The majority of melanomas show constitutive activation of the RAS-RAF-MAP/ERK kinase (MEK)-mitogen-activated
protein kinase (MAPK) pathway. AZD6244 is a selective MEK1/2 …

Sequential cytokine therapy for pressure ulcers: clinical and mechanistic response

MC Robson, DP Hill, PD Smith, X Wang… - Annals of …, 2000 - journals.lww.com
Smith et al 61 have reported that sequential therapy was effective in accelerating healing
in acute surgical incisions; they found the effective sequence to be PDGF-BB followed by …